Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523947 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
A Phase 1 study of HER2-Positive Solid Tumor, sponsored by Yuhan Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 19
- Study locations
NCT05523947: Recruiting Phase 1 study of HER2-Positive Solid Tumor, sponsored by Yuhan Corporation.
NCT05523947 is a Phase 1 study of HER2-Positive Solid Tumor that is actively recruiting participants, run by Yuhan Corporation. The registered enrollment target is 147 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher). The trial reports 19 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05523947, a Phase 1 study of HER2-Positive Solid Tumor, is actively recruiting participants, sponsored by Yuhan Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 19
- Study locations
Study Summary
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Primary Outcome
To assess the safety and tolerability of YH32367
Conditions Studied
Interventions
- DRUG YH32367
Study Locations (19)
Other
- Southern Oncology Clinical Research Unit - Adelaide
- Austin Health - Melbourne
- Breast Cancer Research Centre - WA - Perth
- Blacktown Hospital - Sydney
- Gachon Gil University Medical Center - Incheon
- Korea University Anam Hospital - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- The Catholic University of Korea, St. Mary's hospital - Seoul
- Ulsan University Hospital - Ulsan
Gyeonggi-do
- CHA Bundang Medical Center - Seongnam-si
- Catholic University of Korea St. Vincent's Hospital - Suwon
- Ajou University Hospital - Suwon
Massachusetts
- Dana Farber Cancer Institute - Boston
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Gyeongsangnam-do
- Gyeongsang National University Hospital - Jinju
North Chungcheong
- Chungbuk National University Hospital - Cheongju-si
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
What NCT05523947 shows while recruiting
NCT05523947 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher).
The record links to 1 condition, with HER2-Positive Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YH32367 is the first listed.
NCT05523947 lists 19 locations in 6 states (Other, Gyeonggi-do, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05523947 about?
NCT05523947 is a clinical study titled "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor". This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
What is the current status of trial NCT05523947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2022-08-26. Estimated completion is 2028-04-30.
What conditions does trial NCT05523947 study?
This clinical trial studies the following conditions: HER2-Positive Solid Tumor.
What interventions are being tested in trial NCT05523947?
The interventions under investigation include: YH32367 (DRUG).
Who is sponsoring clinical trial NCT05523947?
This trial is sponsored by Yuhan Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05523947 being conducted?
This trial has 19 study locations across Massachusetts, Tennessee, Gyeonggi-do, Gyeongsangnam-do, North Chungcheong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Positive Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05523947's enrollment target sits among peer trials
147 388th of 2000 higher than 1,610 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06184516 · 147 participants · Phase 2
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI